About DrugSynq
Built by computational chemists who were tired of vendor lock-in.
Founded in 2021 in San Diego, DrugSynq exists because FEP-quality molecular simulation was priced as enterprise software — inaccessible to independent biotech teams and academic drug discovery groups doing exactly the work that needed it most.
Mission
Physics-based drug discovery for every medicinal chemistry team.
The established computational chemistry platforms — Schrödinger, OpenEye, BioLuminate — are seriously capable tools. They're also licensed for large pharma organizations with $1B+ R&D budgets. Meanwhile, the 100-person biotech with a promising kinase target and six months of runway makes synthesis decisions from docking scores and intuition, because FEP-quality predictions weren't financially accessible.
DrugSynq's mission is to close that gap: FEP binding affinity prediction and validated ADMET screening at a price point that works for a medicinal chemistry team of four. Not a simplified version — the same physics, at a scale designed for the programs that actually need it most.
DrugSynq is not a CRO. We do not run wet-lab assays, synthesize compounds, or provide clinical data. All outputs are computational predictions — they inform synthesis decisions but require experimental validation before any regulatory or clinical use.
Origin Story
Started at the UCSD computational chemistry lab in 2021.
Dr. Maya Patel spent three years as a postdoctoral researcher at Schrödinger before joining UCSD as a faculty affiliate. The recurring conversation in every collaborator meeting: "We need FEP-quality predictions but can't afford the license." The workaround — run docking, hope for the best — produced hit rates no better than random for many target classes.
In early 2021, Dr. Patel recruited Ravi Krishnamurthy (computational infrastructure) and Sophie Chen (ADMET modeling) to build a production-grade FEP pipeline that could serve a growing lab without a $500K software contract. Two years of validation work later, DrugSynq opened external access in 2023.
Values
How we build.
Transparent Uncertainty
Every prediction DrugSynq produces includes an error estimate. We will never present a ΔΔG value without its σ. Overconfident predictions are more dangerous than no prediction.
Published Evidence
Performance claims are backed by peer-reviewed papers. If we can't publish the validation methodology and pass peer review, we don't advertise the number. No marketing metrics.
Accessible by Design
Pricing, documentation, and onboarding are designed for teams who can't afford a three-month implementation project. You should be running your first campaign in under an hour.
Location
Torrey Pines, San Diego.
We're located in the Torrey Pines Science Park — the same neighborhood as Illumina, Sorrento Therapeutics, and dozens of biotech companies that are DrugSynq's natural neighbors and partners. The San Diego biotech ecosystem is where the work we care about happens.
Get in Touch